Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae
- PMID: 11353607
- PMCID: PMC90527
- DOI: 10.1128/AAC.45.6.1649-1653.2001
Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae
Abstract
Gatifloxacin (8-methoxy, 7-piperazinyl-3'-methyl) at the MIC selected mutant strains that possessed gyrA mutations at a low frequency (3.7 x 10(-9)) from wild-type strain Streptococcus pneumoniae IID553. AM-1147 (8-methoxy, 7-piperazinyl-3'-H) at the MIC or higher concentrations selected no mutant strains. On the other hand, the respective 8-H counterparts of these two compounds, AM-1121 (8-H, 7-piperazinyl-3'-methyl) and ciprofloxacin (8-H, 7-piperazinyl-3'-H), at one and two times the MIC selected mutant strains that possessed parC mutations at a high frequency (>2.4 x 10(-6)). The MIC of AM-1147 increased for the gyrA mutant strains but not for the parC mutant strains compared with that for the wild-type strain. These results suggest that fluoroquinolones that harbor 8-methoxy groups select mutant strains less frequently and prefer DNA gyrase, as distinct from their 8-H counterparts. The in vitro activities of gatifloxacin and AM-1147 are twofold higher against the wild-type strain, eight- and twofold higher against the first-step parC and gyrA mutant strains, respectively, and two- to eightfold higher against the second-step gyrA and parC double mutant strains than those of their 8-H counterparts. These results indicate that the 8-methoxy group contributes to enhancement of antibacterial activity against target-altered mutant strains as well as the wild-type strain. It is hypothesized that the 8-methoxy group of gatifloxacin increases the level of target inhibition, especially against DNA gyrase, so that it is nearly the same as that for topoisomerase IV inhibition in the bacterial cell, leading to potent antibacterial activity and a low level of resistance selectivity.
Figures
Similar articles
-
Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.Antimicrob Agents Chemother. 2004 Oct;48(10):3954-8. doi: 10.1128/AAC.48.10.3954-3958.2004. Antimicrob Agents Chemother. 2004. PMID: 15388458 Free PMC article.
-
In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.J Antimicrob Chemother. 2004 Sep;54(3):640-7. doi: 10.1093/jac/dkh393. Epub 2004 Aug 18. J Antimicrob Chemother. 2004. PMID: 15317743
-
Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.Antimicrob Agents Chemother. 2001 Nov;45(11):3140-7. doi: 10.1128/AAC.45.11.3140-3147.2001. Antimicrob Agents Chemother. 2001. PMID: 11600369 Free PMC article.
-
Mechanisms and spread of fluoroquinolone resistance in Streptococcus pneumoniae.Res Microbiol. 2000 Jul-Aug;151(6):471-3. doi: 10.1016/s0923-2508(00)00167-4. Res Microbiol. 2000. PMID: 10961461 Review.
-
Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims.J Antimicrob Chemother. 2002 Jun;49(6):893-5. doi: 10.1093/jac/dkf047. J Antimicrob Chemother. 2002. PMID: 12039880 Review. No abstract available.
Cited by
-
Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae.Antimicrob Agents Chemother. 2002 Aug;46(8):2712-5. doi: 10.1128/AAC.46.8.2712-2715.2002. Antimicrob Agents Chemother. 2002. PMID: 12121964 Free PMC article.
-
Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.Antimicrob Agents Chemother. 2002 Jan;46(1):119-24. doi: 10.1128/AAC.46.1.119-124.2002. Antimicrob Agents Chemother. 2002. PMID: 11751121 Free PMC article.
-
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.Antimicrob Agents Chemother. 2003 Aug;47(8):2606-14. doi: 10.1128/AAC.47.8.2606-2614.2003. Antimicrob Agents Chemother. 2003. PMID: 12878526 Free PMC article.
-
In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions.Antimicrob Agents Chemother. 2018 Mar 27;62(4):e01971-17. doi: 10.1128/AAC.01971-17. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29439959 Free PMC article.
-
Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol.Medicine (Baltimore). 2023 Feb 22;102(8):e33092. doi: 10.1097/MD.0000000000033092. Medicine (Baltimore). 2023. PMID: 36827005 Free PMC article.
References
-
- Alovero F L, Pan X-S, Morris J E, Manzo R H, Fisher L M. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob Agents Chemother. 2000;44:320–325. - PMC - PubMed
-
- Beyer R, Pestova E, Millichap J J, Stosor V, Noskin G A, Peterson L R. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob Agents Chemother. 2000;44:798–801. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources